viCARDIA Therapeutics Raises $3.3M with Strategic Business Support to Combat Heart Failure Epidemic
Biotech Startup Leverages Expert Guidance to Secure $3.3MM Funding for Novel Heart Failure Treatment
When Michael Kokesh, J.D., CEO of viCARDIA Therapeutics, faced the challenge of raising capital for his groundbreaking heart failure treatment, he knew that having the right presentation and business strategy would be crucial. Despite being a serial life sciences entrepreneur, Kokesh understood that each venture presents unique challenges.
The Challenge
Heart failure affects over 64 million people worldwide and represents one of the most complex medical challenges of our time. viCARDIA, founded in 2017, had discovered a revolutionary approach: targeting mitochondrial dysfunction as the root cause of heart failure. However, translating this scientific breakthrough into a compelling investment opportunity required expert business guidance.
The Solution
Kokesh connected with Pitch Global and their advisors, Kaustav Chaudhuri (KC) and Axel Tillmann from SBDC’s Tech Futures Group. The team provided comprehensive support in refining viCARDIA’s presentation and business strategy, helping to articulate the company’s value proposition to potential investors.
The care and attention to detail that the Pitch Global Team gave to viCARDIA made all the difference in seeing better acceptance in the investor community.
Michael Kokesh, J.D., CEO of viCARDIA Therapeutics
The Results
With enhanced presentation materials and a refined business strategy, viCARDIA successfully raised $3.3 million in funding. This capital enables the company to advance their novel therapies for heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction (HFpEF), and related neurological and metabolic disorders.
Looking Forward
viCARDIA’s success demonstrates the critical role that business development support plays in helping life sciences startups translate scientific innovation into funded ventures. As the company continues to develop cardioprotective therapies that enhance the bioenergetics of the myocardium, they’re positioned to make a significant impact on the global heart failure epidemic.
Learn more about viCARDIA here
